Market Movers: Oriel Morrison interviews Jennifer Chow, MD and CEO of Chimeric Therapeutics (ASX:CHM)

Link copied to
clipboard

Stockhead’s Market Movers video series features one-on-one interviews showcasing the major announcements of emerging ASX companies.

In this instalment, former CNBC, Sky News, and Bloomberg news anchor Oriel Morrison interviews Jennifer Chow, managing director and CEO of Chimeric Therapeutics (ASX:CHM).

Chimeric Therapeutics is the only clinical stage, cell therapy biotechnology company in Australia. The company’s focus is on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.

To hear more, click above.  

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

Hidden

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

On the Bid

CAR-T therapies are leading the race to cure cancer

September 27, 2022 | Oriel Morrison

Long Shortz

Long Shortz with Optiscan Imaging: To the US - and the moon!

April 4, 2024 | Stockhead TV

Aftermarket

What is amycretin? The new weight-loss pill that's 'twice as effective' as Ozempic

March 15, 2024 | Sera Bozza at Body and Soul